The field of research in bladder cancer has seen significant advances in recent years. Next-
generation sequencing has identified the genes most mutated in bladder cancer. This …

Non-muscle-invasive bladder cancer (NMIBC) is an early-stage cancer without invasion into
the detrusor muscle layer. Transurethral resection of bladder tumour (TURBT) is a diagnostic …

Bladder cancer is the fifth most prevalent cancer in the US, yet is understudied, and few
laboratory models exist that reflect the biology of the human disease. Here, we describe a …

FGFRs are receptor tyrosine kinases with a role in several biological processes, such as the
regulation of development and tissue repair. However, alterations in FGFRs 1–4, such as …

Molecular stratification can improve the management of advanced cancers, but requires
relevant tumor samples. Metastatic urothelial carcinoma (mUC) is poised to benefit given a …

Bladder cancer incurs a higher lifetime treatment cost than other cancers due to frequent
recurrence of non-invasive disease. Improved prognostic biomarkers and localized therapy …

Upper urinary tract urothelial carcinoma (UTUC) is one of the common urothelial cancers. Its
molecular pathogenesis, however, is poorly understood, with no useful biomarkers available …

Ageing is correlated with elevated bladder cancer incidence, morbidity and mortality.
Advanced age is also associated with elevated markers of chronic inflammation and …

The combination of targeted therapy with immune checkpoint inhibition (ICI) is an area of
intense interest. We studied the interaction of fibroblast growth factor receptor (FGFR) …

Context In the management of urothelial carcinoma, determination of the pathological grade
aims at stratifying tumours into different prognostic groups to allow evaluation of treatment …